```html

Radiation Pneumonitis – A Complete Patient‑Friendly Guide

Overview

Radiation pneumonitis (RP) is an inflammatory reaction of the lung tissue that occurs after exposure to therapeutic radiation, most commonly given for cancers of the chest such as lung, breast, esophageal, or lymphoma. The inflammation can cause swelling, fluid accumulation, and impaired gas exchange.

Who it affects:

• Adults receiving external‑beam radiotherapy (EBRT) to the thorax.
• Patients with underlying lung disease (COPD, interstitial lung disease) are more vulnerable.
• Older age (≥ 65 years) and smokers have a higher incidence.

Prevalence: The incidence varies with radiation dose, technique, and patient factors. In modern series using intensity‑modulated radiotherapy (IMRT) or proton therapy, clinically significant RP occurs in 5‑15 % of treated patients, whereas older 2‑D techniques reported rates up to 30 % (Mayo Clinic, 2022).

Symptoms

Symptoms typically appear 4‑12 weeks after completing radiation but can develop as early as 2 weeks or as late as 6 months. The severity ranges from mild, self‑limited cough to life‑threatening respiratory failure.

Common clinical manifestations

• Dry, non‑productive cough – often the first sign.
• Dyspnea (shortness of breath) – may be exertional at first, progressing to at‑rest.
• Fever – usually low‑grade (≤ 38.5 °C); higher fevers should raise suspicion for infection.
• Chest discomfort or pleuritic pain – sharp pain that worsens with deep breaths.
• Fatigue – generalized tiredness beyond normal cancer‑related fatigue.
• Wheezing or crackles on auscultation – fine “rales” heard over the affected lung field.
• Slight weight loss – due to increased work of breathing.

Severe or atypical symptoms (prompt medical evaluation)

• Sudden worsening of dyspnea or new onset of severe shortness of breath.
• High‑grade fever (> 38.5 °C) or chills.
• Cough producing thick, purulent sputum (suggests superimposed infection).
• Chest pain radiating to the shoulder or back.
• Rapid heart rate (> 110 bpm) or low oxygen saturation (< 90 % on room air).

Causes and Risk Factors

Radiation pneumonitis is not a disease you “catch”; it results from direct injury to lung cells and the ensuing immune response.

Primary cause

• Therapeutic radiation – ionizing radiation damages alveolar epithelium and capillary endothelium, triggering an inflammatory cascade.

Major risk factors

• Total radiation dose – doses > 30 Gy to large lung volumes raise risk dramatically.
• Volume of lung irradiated – a V20 (percentage of lung receiving ≥ 20 Gy) > 35 % is associated with a > 20 % incidence of RP.
• Concurrent chemotherapy – especially agents such as taxanes, platinum compounds, and gemcitabine that sensitize lung tissue.
• Pre‑existing lung disease – COPD, asthma, pulmonary fibrosis.
• Smoking history – current or former smokers have reduced pulmonary reserve.
• Age ≥ 65 years – age‑related decline in repair mechanisms.
• Female sex – some series suggest slightly higher rates, possibly related to smaller thoracic cavity.
• Genetic predisposition – polymorphisms in cytokine genes (e.g., TGFB1, IL‑6) are under investigation.

Diagnosis

Diagnosing RP is largely clinical but must exclude infection, tumor recurrence, or pulmonary embolism.

Step‑by‑step diagnostic approach

1. History & physical exam – timing relative to radiation, symptom pattern, auscultation findings.
2. Chest imaging
   • CT scan (high‑resolution) – shows ground‑glass opacities or consolidation within the radiation field; “radiation shadow” pattern is classic.
   • Chest X‑ray – may reveal diffuse haziness but is less sensitive.
3. Pulmonary function tests (PFTs) – typically show a decrease in diffusing capacity for carbon monoxide (DLCO) and a mild restrictive pattern.
4. Laboratory studies
   • Complete blood count – look for leukocytosis (infection) vs. normal counts.
   • CRP/ESR – often elevated but non‑specific.
5. Bronchoscopy (select cases) – performed when infection or tumor cannot be ruled out; bronchoalveolar lavage fluid is cultured.

Diagnostic criteria (per American Society for Radiation Oncology) include: symptoms compatible with RP, radiographic changes confined to the irradiated field, and the absence of another plausible cause.

Treatment Options

Management aims to reduce inflammation, relieve symptoms, and prevent progression to fibrosis.

Pharmacologic therapy

• Corticosteroids – first‑line.
  • Prednisone 1 mg/kg/day (max 60 mg) for 4‑6 weeks, then a gradual taper over 6‑12 weeks based on response.
  • Alternative: oral dexamethasone 6‑10 mg/day.
• Bronchodilators – inhaled short‑acting β2‑agonists for wheeze; consider long‑acting agents if underlying COPD.
• Antitussives – dextromethorphan for persistent cough.
• Antibiotics – only if bacterial infection is suspected or confirmed.
• Immunomodulators (research setting) – agents such as pentoxifylline or pirfenidone have been explored for steroid‑refractory cases, but data remain limited.

Supportive & procedural measures

• Oxygen therapy – titrated to maintain SpO₂ ≥ 92 % (or ≥ 88 % in COPD patients).
• Pulmonary rehabilitation – breathing exercises, graded walking programs improve functional capacity.
• Mechanical ventilation – reserved for severe respiratory failure; ideally in an intensive‑care setting.
• Radiation dose modification – if RP develops during a course, the remaining fractions may be reduced or omitted after multidisciplinary discussion.

Lifestyle & adjunctive care

• Smoking cessation – nicotine replacement or prescription meds (varenicline, bupropion).
• Hydration – thin secretions and improve mucociliary clearance.
• Balanced nutrition – adequate protein (1.2‑1.5 g/kg) to support tissue repair.

Living with Radiation Pneumonitis

While RP can be frightening, many patients improve with proper treatment. Below are practical tips for daily life.

Self‑monitoring

• Record daily temperature, respiratory rate, and shortness of breath score (e.g., Borg scale).
• Keep a symptom diary – note triggers (e.g., exertion, cold air) and medication timing.

Activity guidance

• Start with gentle activities (slow walking, seated stretches) and increase gradually as tolerated.
• Avoid high‑intensity exertion until oxygen saturation stabilizes.

Environmental considerations

• Use a humidifier (30‑40 % humidity) to keep airways moist.
• Avoid exposure to pollutants, strong odors, and second‑hand smoke.
• Wear a surgical mask when in crowded indoor areas during flu season.

Medication adherence

• Take steroids exactly as prescribed; never stop abruptly to avoid adrenal insufficiency.
• Set alarms or use a pill‑box to prevent missed doses.

Follow‑up schedule

• First follow‑up with oncology or pulmonology 2 weeks after starting steroids.
• Repeat chest CT or X‑ray at 6‑8 weeks to document radiographic response.
• Pulmonary function tests every 3‑6 months for the first year.

Prevention

Preventing RP starts with the radiation oncology team, but patients also play a role.

Radiation planning strategies

• Use modern techniques (IMRT, VMAT, proton therapy) to spare healthy lung tissue.
• Limit V20 to < 35 % and mean lung dose (MLD) to < 20 Gy whenever possible (ASTRO guidelines).
• Consider breath‑hold or gating methods for left‑sided breast cancer to reduce lung exposure.

Medical prophylaxis (selected cases)

• Low‑dose steroids (e.g., prednisone 10 mg daily) have been trialed in high‑risk patients, but routine use is not currently recommended by NCCN.
• Statins (e.g., atorvastatin) are under investigation for anti‑inflammatory effects.

Lifestyle measures before, during, and after therapy

• Quit smoking at least 6 weeks before radiation; nicotine replacement can improve outcomes.
• Maintain optimal control of COPD or asthma (inhaled steroids, bronchodilators).
• Vaccinate against influenza and pneumococcus to reduce superimposed infections.

Complications

If RP is not promptly recognized or inadequately treated, it can progress to serious sequelae.

• Chronic radiation fibrosis – irreversible scarring that reduces lung compliance and may cause permanent dyspnea.
• Recurrent infections – damaged lung tissue is a nidus for bacterial or fungal colonization.
• Bronchial obstruction – inflammation can cause stenosis, leading to atelectasis.
• Pulmonary hypertension – chronic hypoxia may increase vascular resistance.
• Respiratory failure – severe cases require mechanical ventilation and carry a mortality of 10‑30 % (Cleveland Clinic, 2021).

When to Seek Emergency Care

---

**References** (accessed April 2026):

• Mayo Clinic. Radiation pneumonitis. https://www.mayoclinic.org
• American Society for Radiation Oncology (ASTRO). Consensus guidelines for thoracic radiation. 2022.
• Cleveland Clinic. Radiation‑induced lung injury. 2021.
• National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology – Lung Cancer. Version 3.2025.
• World Health Organization. Cancer radiotherapy safety. 2023.
• NIH National Cancer Institute. Radiation therapy side effects. 2024.

```